All In Biotech

Free tool

FAERS Monitor: Methyldopa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018934 or its brand name (Methyldopa, Methyldopa). Reports on generic versions are filed under their own applications.

Reports

4,936

Serious

4,615

93% of reports

Hospitalization

1,654

Death reported

231

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • foetal exposure during pregnancy1,364
  • premature baby930
  • maternal exposure during pregnancy838
  • exposure during pregnancy698
  • premature delivery584
  • low birth weight baby389
  • drug ineffective268
  • hypertension259
  • off label use231
  • foetal growth restriction216
  • pre-eclampsia208
  • atrial septal defect196
  • dyspnoea195
  • caesarean section168
  • live birth165

Reports by year received

View as table
YearReports
200437
200571
200663
200760
200899
2009127
2010112
2011161
2012161
2013166
2014253
2015198
2016219
2017245
2018468
2019431
2020393
2021346
2022329
2023257
2024305
2025199
2026236

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,223 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
low birth weight babySignal389219.3198.880,213
pre-eclampsiaSignal208195.0170.238,211
premature deliverySignal584162.2150.090,028
foetal growth restrictionSignal216156.9137.432,135
premature babySignal930135.8128.0120,671
atrial septal defectSignal196102.188.919,070
live birthSignal16585.773.713,463
foetal exposure during pregnancySignal1,36472.769.595,140
caesarean sectionSignal16862.353.79,939
exposure during pregnancySignal69848.445.232,076
maternal exposure during pregnancySignal83840.438.032,024
hypertensionSignal2595.24.6886
dyspnoea1951.51.329
off label use2311.11.03
drug ineffective2680.90.86

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.